NGAL/Lipocalin-2, His, Cynomolgus
NGAL/Lipocalin-2, His, Cynomolgus

Immobilized NGAL/Lipocalin-2, His, Cynomolgus, His Tag at 0.5 μg/ml (100 μl/well) on the plate. Dose response curve for Anti-NGAL Antibody, hFc Tag with the EC50 of 3.5ng/ml determined by ELISA.

NGAL/Lipocalin-2, His, Cynomolgus

The purity of NGAL/Lipocalin-2, His, Cynomolgus is greater than 95% as determined by SEC-HPLC.

NGAL/Lipocalin-2, His, Cynomolgus

NGAL/Lipocalin-2, His, Cynomolgus on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

NGAL/Lipocalin-2, His, Cynomolgus

Acute kidney injury (AKI) is one of the most common complications of various serious conditions, and early diagnosis is therefore critical for the treatment of AKI. Recent evidence demonstrates that neutrophil gelatinase- associated lipocalin (NGAL) is closely associated with AKI. Several experimental and clinical studies have shown that the expression of urine and serum NGAL increases significantly in AKI. NGAL shows potential to be a new effective early biochemical marker of AKI. Further studies are needed to confirm the significant advantages of NGAL in the diagnosis of early AKI and its value in clinical applications.
Z04878
¥63,425.00

Ask us a question
Product Introduction
Species Cynomolgus
Protein Construction
NGAL/Lipocalin-2 (Gln21-Gly198)
Accession # XP_005580845.3		 His
N-term C-term
Purity > 95% as determined by Bis­Tris PAGE 
Endotoxin Level Less than 1EU per μg by the LAL method.
Biological Activity Measured by its binding ability in a functional ELISA.Test result was comparable to standard batch.
Expression System HEK293
Theoretical Molecular Weight 21.51 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 25-30 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22μm filtered solution in PBS (pH 7.4).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles.

Examples
  • NGAL/Lipocalin-2, His, Cynomolgus
    • NGAL/Lipocalin-2, His, Cynomolgus

    Immobilized NGAL/Lipocalin-2, His, Cynomolgus, His Tag at 0.5 μg/ml (100 μl/well) on the plate. Dose response curve for Anti-NGAL Antibody, hFc Tag with the EC50 of 3.5ng/ml determined by ELISA.

  • NGAL/Lipocalin-2, His, Cynomolgus
    • NGAL/Lipocalin-2, His, Cynomolgus

    The purity of NGAL/Lipocalin-2, His, Cynomolgus is greater than 95% as determined by SEC-HPLC.

  • NGAL/Lipocalin-2, His, Cynomolgus
    • NGAL/Lipocalin-2, His, Cynomolgus

    NGAL/Lipocalin-2, His, Cynomolgus on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.


Background
Target Background Acute kidney injury (AKI) is one of the most common complications of various serious conditions, and early diagnosis is therefore critical for the treatment of AKI. Recent evidence demonstrates that neutrophil gelatinase- associated lipocalin (NGAL) is closely associated with AKI. Several experimental and clinical studies have shown that the expression of urine and serum NGAL increases significantly in AKI. NGAL shows potential to be a new effective early biochemical marker of AKI. Further studies are needed to confirm the significant advantages of NGAL in the diagnosis of early AKI and its value in clinical applications.
Synonyms NGAL; Lipocalin-2; Oncogene 24p3; p25; Siderocalin LCN2; MSFI

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.